|
Silverman, Kenneth; Holtyn, August F; Subramaniam, Shrinidhi (2018) Behavior analysts in the war on poverty: Developing an operant antipoverty program. Exp Clin Psychopharmacol 26:515-524
|
|
Carbonaro, Theresa M; Johnson, Matthew W; Hurwitz, Ethan et al. (2018) Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences. Psychopharmacology (Berl) 235:521-534
|
|
Jarvis, Brantley P; DeFulio, Anthony; Long, Lauren et al. (2018) Factors associated with using opiates while under extended-release naltrexone blockade: A descriptive pilot study. J Subst Abuse Treat 85:56-60
|
|
Huhn, Andrew S; Garcia-Romeu, Albert Perez; Dunn, Kelly E (2018) Opioid Overdose Education for Individuals Prescribed Opioids for Pain Management: Randomized Comparison of Two Computer-Based Interventions. Front Psychiatry 9:34
|
|
Morris, David H; Davis, Alan K; Lauritsen, Kirstin J et al. (2018) Substance use consequences, mental health problems, and readiness to change among Veterans seeking substance use treatment. J Subst Abuse Treat 94:113-121
|
|
Pacek, Lauren R; McClernon, F Joseph; Rass, Olga et al. (2018) Perceived risk of developing smoking-related disease among persons living with HIV. AIDS Care 30:1329-1334
|
|
Jarvis, Brantley P; Holtyn, August F; Subramaniam, Shrinidhi et al. (2018) Extended-release injectable naltrexone for opioid use disorder: a systematic review. Addiction 113:1188-1209
|
|
Huhn, Andrew S; Berry, Meredith S; Dunn, Kelly E (2018) Systematic review of sex-based differences in opioid-based effects. Int Rev Psychiatry :1-10
|
|
Davis, Alan K; Barsuglia, Joseph P; Lancelotta, Rafael et al. (2018) The epidemiology of 5-methoxy- N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption. J Psychopharmacol 32:779-792
|
|
Davis, Alan K; Renn, Elise; Windham-Herman, Austin-Marley et al. (2018) A Mixed-Method Analysis of Persisting Effects Associated with Positive Outcomes Following Ibogaine Detoxification. J Psychoactive Drugs 50:287-297
|
Showing the most recent 10 out of 288 publications
